p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Cell

• Publication date

  2003-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1535-6108(03)00079-5PMID 12726864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemosensitivity linked to p73 function.

  2003cited by this paper
• Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma.

  2003cited by this paper
• p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.

  2002cited by this paper
• Dissecting p53 tumor suppressor functions in vivo.

  2002cited by this paper
• Live or let die: the cell's response to p53

  2002cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia

  2002cited by this paper
• Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities*

  2002cited by this paper
• ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors

  2002cited by this paper
• DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes.

  2002cited by this paper
• Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck

  2002cited by this paper
• Transactivation-deficient ΔTA-p73 Acts as an Oncogene

  2002cited by this paper
• Transactivation-deficient DeltaTA-p73 acts as an oncogene.

  2002cited by this paper
• Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53

  2001cited by this paper
• Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.

  2001cited by this paper
• Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain

  2001cited by this paper
• TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.

  2001cited by this paper
• Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.

  2001cited by this paper
• Assessing TP53 status in human tumours to evaluate clinical outcome

  2001cited by this paper
• Oncogenes Induce and Activate Endogenous p73 Protein*

  2001cited by this paper
• p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

  2000cited by this paper
• A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

  2000cited by this paper
• Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53.

  2000cited by this paper
• Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.

  2000cited by this paper
• Role of the p53-homologue p73 in E2F1-induced apoptosis

  2000cited by this paper
• Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73*

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Role for the p53 homologue p73 in E2F-1-induced apoptosis

  2000influential reference
• Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

  1999cited by this paper
• Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.

  1999cited by this paper
• p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

  1999cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis.

  1999cited by this paper
• Cumulative prognostic value of p53 mutations and bcl‐2 protein expression in head‐and‐neck cancer treated by radiotherapy

  1999cited by this paper
• To Live or Let Die

  1999cited by this paper
• p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage

  1999cited by this paper
• Interaction of c-Abl and p73α and their collaboration to induce apoptosis

  1999cited by this paper
• Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity

  1998cited by this paper
• Mutant p53 protein expression interferes with p53-independent apoptotic pathways

  1998cited by this paper
• Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.

  1997cited by this paper
• p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.

  1996cited by this paper
• The p53 and mdm‐2 genes in human testicular germ‐cell tumors

  1995cited by this paper
• p53 status and the efficacy of cancer therapy in vivo.

  1994cited by this paper
• Transcriptional activation by p53 correlates with suppression of growth but not transformation.

  1994cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?

  2025cites this paper
• Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer

  2024cites this paper
• Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL

  2024cites this paper
• Different mutational profiles of subcutaneous panniculitis-like T-cell lymphoma and lupus panniculitis: an additional case series.

  2024cites this paper
• Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance

  2024cites this paper
• Advancements in p53-Based Anti-Tumor Gene Therapy Research

  2024cites this paper
• Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer

  2024cites this paper
• Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer

  2024cites this paper
• Targeted MDM2 degradation reveals a new vulnerability for p53 inactivated triple negative breast cancer.

  2023cites this paper
• BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate

  2023cites this paper
• MiR-223-3p increases resistance of colorectal cancer cells to 5-fluorouracil via targeting SORBS1.

  2023cites this paper
• Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways

  2023cites this paper
• Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

  2023cites this paper
• p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act

  2023cites this paper
• Genomic alterations and diagnosis of renal cancer

  2023cites this paper
• Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro

  2022cites this paper
• Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas

  2022cites this paper
• Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment

  2022cites this paper
• The miR-106b-25 cluster mediates drug resistance in myeloid leukaemias by inactivating multiple apoptotic genes

  2022cites this paper
• Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation

  2022cites this paper
• Benign single-nucleotide polymorphisms in the coding region of TP53: finding the needles in a haystack of pathogenic variants.

  2022cites this paper
• Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer

  2022cites this paper
• Age-specific oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory?

  2022cites this paper
• Establishment and Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma

  2021cites this paper
• Pathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas

  2021cites this paper
• Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade

  2021cites this paper
• Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma

  2021cites this paper
• Genetic associations of TP53 codon Pro72Arg polymorphism (rs1042522) in coronary artery disease: A meta-analysis of candidate genetic mutants

  2021cites this paper
• Upregulation of p53 by tannic acid treatment suppresses the proliferation of human colorectal carcinoma

  2021cites this paper
• Effects of HRG and TP73 gene variations on ovarian response

  2021cites this paper
• Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era

  2021cites this paper
• TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

  2021cites this paper
• 8-OHdG repair is associated with platinum sensitivity in high-grade serous ovarian carcinoma

  2021cites this paper
• TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy

  2021cites this paper
• Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role

  2021cites this paper
• Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer

  2020cites this paper
• Deep Next Generation Sequencing Identifies Somatic Mutational Signature in Egyptian Colorectal Cancer Patients

  2020cites this paper
• Small Molecules Targeting Mutant P53: A Promising Approach For Cancer Treatment.

  2020cites this paper
• Multimodal genetic features correlate with poor response to neoadjuvant chemoradiotherapy and high recurrence risk in Chinese patients with stage IB-IIA cervical cancer

  2020cites this paper
• Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk

  2020cites this paper
• Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients

  2020cites this paper
• Linkage disequilibrium and haplotypes of five TP53 polymorphisms in oesophageal cancer patients

  2020cites this paper
• Functional genetic variants of CTNNBIP1 predict platinum treatment response of Chinese epithelial ovarian cancer patients

  2020cites this paper
• TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer

  2019cites this paper
• Metformin Inhibits Growth of Breast Cancer Cell T47 through Decreasing Expression of Protein P53, BCL2 and Cyclin D1

  2019cites this paper
• Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.

  2019cites this paper
• Bifunctional ligand design for modulating mutant p53 aggregation in cancer

  2019cites this paper
• Impaired telomere integrity and rRNA biogenesis in PARN‐deficient patients and knock‐out models

  2019cites this paper
• The role of autophagy and Beclin-1 in radiotherapy-induced apoptosis in thyroid carcinoma cells.

  2019cites this paper
• Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model

  2019cites this paper
• Role of p53 Family Proteins in Metformin Anti-Cancer Activities

  2019cites this paper
• Regulators of Oncogenic Mutant TP53 Gain of Function

  2018cites this paper
• p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance

  2018cites this paper
• P53 in Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• Mutant p53 as a guardian of the cancer cell

  2018cites this paper
• Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low‐risk, nontraditional patients

  2018cites this paper
• Molecular Determinants of Head and Neck Cancer

  2018influential citation
• TP53 rs1625895 is Related to Breast Cancer Incidence and Early Death in Iranian Population

  2018cites this paper
• DUSP2 methylation is a candidate biomarker of outcome in head and neck cancer.

  2018cites this paper
• TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

  2018cites this paper
• Complexes formed by mutant p53 and their roles in breast cancer

  2018cites this paper
• TP53 single nucleotide polymorphism (rs1042522) in Iranian patients with coronary artery disease.

  2018cites this paper
• Contemporary Oral Oncology: Diagnosis and Management

  2018cites this paper
• Mutant p53 proteins alter signaling pathways involved in autophagy and redox regulation in cancer cells

  2017cites this paper
• Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk

  2017cites this paper
• Particular gene upregulation and p53 heterogeneous expression in TP53-mutated maxillary carcinoma

  2017cites this paper
• TP53 Codon 72 Genetic Polymorphism, rs1042522, Modifies the Association Between Tobacco Smoking and Breast Cancer Risk

  2017cites this paper
• P73 G4C14‐to‐A4T14 polymorphism is associated with survival in advanced non‐small cell lung cancer patients

  2017cites this paper
• Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation

  2017cites this paper
• Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

  2017cites this paper
• Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand

  2017cites this paper
• Runx3 and Cell Fate Decisions in Pancreas Cancer.

  2017cites this paper
• Role of Genetic Variations in Determining Treatment Outcome in Head and Neck Cancer

  2017cites this paper
• MOLECOLARE Serine 249 phosphorylation and Pin 1-induced isomerization activate mutant p 53 R 249 S gain-of-function and promote cross-talk with JAK / STAT 1 signalling in hepatocellular carcinoma

  2017cites this paper
• Biological Basis of Treatment Failure

  2017cites this paper
• Title Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer

  2017cites this paper
• Targeting mutant p53 in cancer: a long road to precision therapy

  2017cites this paper
• Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer.

  2017cites this paper
• Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation.

  2017cites this paper
• Therapeutic targeting of chemotherapy-resistant colorectal cancer stem cells with p73- and TRAIL-based small molecules

  2016cites this paper
• p53 family interactions and yeast: together in anticancer therapy.

  2016cites this paper
• Genetic Modifiers of the p53 Pathway.

  2016cites this paper
• Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways

  2016cites this paper
• TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response

  2016cites this paper
• Evaluation of P53 Polymorphism Susceptibility in Oral Cancer in Population From Gujarat, India

  2016cites this paper
• TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma

  2016cites this paper
• The role of p53 in cancer drug resistance and targeted chemotherapy

  2016cites this paper
• Ac ce pt ed M an us cr ip t p 53 family interactions and yeast : together in anticancer therapy

  2016cites this paper
• Oncogenic Intra-p53 Family Member Interactions in Human Cancers

  2016cites this paper
• Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

  2016cites this paper
• Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years’ Follow-Up

  2016cites this paper
• The potential role of the oxidoreductase, NQO2, in breast cancer

  2015cites this paper
• The clinical translational potential of p53-related alterations as cancer biomarkers.

  2015cites this paper
• TP53: an oncogene in disguise

  2015cites this paper
• TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth

  2015cites this paper
• Lack of influence of TP53 Arg72Pro and 16bp duplication polymorphisms on risk of breast cancer in Iran.

  2015cites this paper
• Nuclear localization of the caspase-3-cleaved form of p73 in anoikis

  2015cites this paper
• Sentinel Gene Within Cell Territory and Molecular Platforms in Cancer: Methylation Diversity of p53 Gene in Brain Tumors

  2015cites this paper
• Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population.

  2015cites this paper